Venetoclax: A new wave in hematooncology.

[1]  Nam‐Hoon Kim,et al.  Combination of BR101801 and Venetoclax Demonstrates Synergistic Activity in DLBCL Cell Lines Harboring Double Hit and Double Expressor Alterations , 2017 .

[2]  R. Gascoyne,et al.  BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL , 2017 .

[3]  M. Konopleva,et al.  Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial , 2017 .

[4]  A. Wei,et al.  Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes , 2017 .

[5]  F. Hernandez-Ilizaliturri,et al.  Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL) , 2017 .

[6]  A. Letai,et al.  Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma , 2017 .

[7]  J. Gribben,et al.  Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy , 2017 .

[8]  A. Letai,et al.  Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia , 2017 .

[9]  R. Hájek,et al.  PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017 , 2017, Immunology.

[10]  N. Nishimura,et al.  BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. , 2017, Blood.

[11]  J. Gribben,et al.  The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy. , 2017 .

[12]  S. Dawson,et al.  Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study. , 2017 .

[13]  A. Salem,et al.  Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia , 2017, Clinical Pharmacokinetics.

[14]  H. Carraway,et al.  Emerging therapies for acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[15]  A. Salem,et al.  Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma , 2017, Journal of clinical pharmacology.

[16]  M. Amiot,et al.  Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14) , 2017, Haematologica.

[17]  T. Kipps,et al.  Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. , 2017, The Lancet. Oncology.

[18]  T. Kipps,et al.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Salles,et al.  Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma , 2016 .

[20]  M. Amiot,et al.  Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study , 2016 .

[21]  A. Chanan-Khan,et al.  Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma , 2016 .

[22]  T. Kipps,et al.  Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323) , 2016 .

[23]  G. Salles,et al.  Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia , 2016 .

[24]  Jeffrey A Jones,et al.  Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib , 2016 .

[25]  R. Hájek,et al.  PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future , 2016, Oncoimmunology.

[26]  A. Salem,et al.  Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL‐2 Inhibitor: Results of a Single‐ and Multiple‐Dose Study , 2016, Journal of clinical pharmacology.

[27]  A. Salem,et al.  Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 Inhibitor , 2016, Journal of clinical pharmacology.

[28]  Yonghong Shi,et al.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. , 2016, Blood.

[29]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[30]  M. Kersten,et al.  Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. , 2016, Blood.

[31]  L. Laurenti,et al.  BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. , 2016, Blood.

[32]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[33]  G. Gordon,et al.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.

[34]  M. Amiot,et al.  Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models , 2016, Molecular Cancer Therapeutics.

[35]  R. Hájek,et al.  Monoclonal antibodies - A new era in the treatment of multiple myeloma. , 2016, Blood reviews.

[36]  Zhichao Zhang,et al.  Bcl‐2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT‐737, ABT‐263 and ABT‐199 by impeding direct binding , 2016, British journal of pharmacology.

[37]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[38]  S. Lonial,et al.  Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax , 2015, Leukemia.

[39]  I. Flinn,et al.  Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies , 2015 .

[40]  A. Ting,et al.  miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies , 2015, Molecular Cancer.

[41]  R. Gascoyne,et al.  Cell of origin of transformed follicular lymphoma. , 2015, Blood.

[42]  Jerry Pelletier,et al.  Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim , 2015, BMC Cancer.

[43]  S. Misra,et al.  Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics , 2015, Oncotarget.

[44]  M. Davids,et al.  The BCL2 antagonist ABT‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild‐type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells , 2015, British journal of haematology.

[45]  A. Letai,et al.  BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics , 2015, Leukemia.

[46]  M. Keating,et al.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia , 2015, Clinical Cancer Research.

[47]  T. Kipps,et al.  A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia , 2015, Leukemia & lymphoma.

[48]  Dolores Diaz,et al.  Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.

[49]  Jeffrey A Jones,et al.  Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia , 2015, Leukemia.

[50]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[51]  S. Mazumder,et al.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies , 2015, Cell Death and Disease.

[52]  Y. Pekarsky,et al.  Role of miR-15/16 in CLL , 2014, Cell Death and Differentiation.

[53]  S. Treon,et al.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.

[54]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[55]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[56]  K. Young,et al.  MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma , 2013, Advances in anatomic pathology.

[57]  M. Amiot,et al.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma , 2013, Leukemia.

[58]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[59]  J. Downing,et al.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. , 2012, Blood.

[60]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[61]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[62]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  I. Lossos,et al.  Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities , 2012, Modern Pathology.

[64]  C. Ortolani.  Flow Cytometry of Hematological Malignancies , 2011 .

[65]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[66]  S. Montoto,et al.  Transformation of indolent B-cell lymphomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[68]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[69]  S. Lowe,et al.  Tumor suppressive functions of p53. , 2009, Cold Spring Harbor perspectives in biology.

[70]  M. Ghielmini,et al.  How I treat mantle cell lymphoma. , 2009, Blood.

[71]  G. Gores,et al.  Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  M. Butterworth,et al.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. , 2009, Blood.

[73]  B. Hoffman,et al.  Apoptotic signaling by c-MYC , 2008, Oncogene.

[74]  Sanjeev Banerjee,et al.  Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo , 2008, Cancer biology & therapy.

[75]  C. Pui,et al.  Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[77]  S. Varambally,et al.  Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition , 2007, Proceedings of the National Academy of Sciences.

[78]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[79]  C. Mitsiades,et al.  Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling. , 2007 .

[80]  J. Partanen,et al.  c-Myc Blazing a Trail of Death: Coupling of the Mitochondrial and Death Receptor Apoptosis Pathways by c-Myc , 2007, Cell cycle.

[81]  K. Basso,et al.  A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. , 2007, Cancer cell.

[82]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[83]  R. Bociek,et al.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[85]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[86]  Irene Ghobrial,et al.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. , 2006, Blood.

[87]  L. Penn,et al.  The Oscar-worthy role of Myc in apoptosis. , 2006, Seminars in cancer biology.

[88]  G. Evan,et al.  Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression in Vivo* , 2006, Journal of Biological Chemistry.

[89]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[90]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[91]  Lin Chen,et al.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.

[92]  B. Cookson,et al.  Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells , 2005, Infection and Immunity.

[93]  S. Korsmeyer,et al.  Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells , 2005, Science.

[94]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[95]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[96]  A. Gunasekera,et al.  Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.

[97]  John L Cleveland,et al.  Myc pathways provoking cell suicide and cancer , 2003, Oncogene.

[98]  K. Kinzler,et al.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[100]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[101]  T. Chittenden.  BH3 domains: intracellular death-ligands critical for initiating apoptosis. , 2002, Cancer cell.

[102]  David Botstein,et al.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[103]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[104]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[105]  A. Strasser,et al.  BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death , 2000, Cell.

[106]  A. Strasser,et al.  FAS Ligand, Bcl-2, Granulocyte Colony-Stimulating Factor, and p38 Mitogen-Activated Protein Kinase , 2000, The Journal of experimental medicine.

[107]  Michael Baudis,et al.  t(11;14)‐positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B‐cell chronic lymphocytic leukemia , 2000, Genes, chromosomes & cancer.

[108]  A. Strasser,et al.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[109]  H. Lodish,et al.  Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.

[110]  N. Motoyama,et al.  bcl-x Prevents Apoptotic Cell Death of Both Primitive and Definitive Erythrocytes at the End of Maturation , 1999, The Journal of experimental medicine.

[111]  J. Taubenberger,et al.  Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. , 1998, The American journal of pathology.

[112]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[113]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[114]  K. Franssila,et al.  DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study. , 1996, Blood.

[115]  L. Frati,et al.  bcl‐2/bax mRNA expression ratio as prognostic factor in low‐grade urinary bladder cancer , 1996, International journal of cancer.

[116]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[117]  T. Kameya,et al.  Expression of bcl‐2 oncogene protein is prevalent in small cell lung carcinomas , 1995, The Journal of pathology.

[118]  R. Gascoyne,et al.  Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. , 1995, American journal of clinical pathology.

[119]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[120]  H. Joensuu,et al.  Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.

[121]  M. Dyer,et al.  BCL2 translocations in leukemias of mature B cells. , 1994, Blood.

[122]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[123]  C. Mecucci,et al.  Chromosome 11q rearrangements in B non Hodgkin's lymphoma , 1992, British journal of haematology.

[124]  M Schena,et al.  Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. , 1992, Blood.

[125]  R. Gressin,et al.  Non‐Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma? , 1991, British journal of haematology.

[126]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[127]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[128]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .